About this trial
This study is to compare Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma
Patient Profile
Patients with relapsed or refractory multiple myeloma
Where’s this trial being run?
Beaumont Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | EXCALIBER-RRMM |
|---|---|
| Number: | 21-10 |
| Full Title: | CC-220-MM-002: A Phase 3, Randomised, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM) |
| Principal Investigator: | Dr John Quinn |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Bristol-Myers Squibb |
| Recruitment Started: |
Global: Jun-2022 Ireland: May-2023 |
| Global Recruitment Target: | Approx. 864 patients |
|---|---|
| Ireland Recruitment Target: | 2-3 patients per site |